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Abstract
Purpose Human amniotic fluid comprises cells with high
differentiation capacity, thus representing a potential cell
source for skin tissue engineering. In this experimental
study, we investigated the ability of human amniotic fluid
derived cells to substitute dermal fibroblasts and support
epidermis formation and stratification in a humanized
animal model.
Methods Dermo-epidermal skin grafts with either am-
niocytes or with fibroblasts in the dermis were compared in
a rat model. Full-thickness skin wounds on the back of
immuno-incompetent rats were covered with skin grafts
with (1) amniocytes in the dermis, (2) fibroblasts in the
dermis, or, (3) acellular dermis. Grafts were excised 7 and
21 days post transplantation. Histology and immunofluo-
rescence were performed to investigate epidermis forma-
tion, stratification, and expression of established skin
markers.
Results The epidermis of skin grafts engineered with
amniocytes showed near-normal anatomy, a continuous
basal lamina, and a stratum corneum. Expression patterns
for keratin 15, keratin 16, and Ki67 were similar to grafts
with fibroblasts; keratin 1 expression was not yet fully
established in all suprabasal cell layers, expression of
keratin 19 was increased and not only restricted to the basal
cell layer as seen in grafts with fibroblasts. In grafts with
acellular dermis, keratinocytes did not survive.
Conclusion Dermo-epidermal skin grafts with amnio-
cytes show near-normal physiological behavior suggesting
that amniocytes substitute fibroblast function to support the
essential cross-talk between mesenchyme and epithelia
needed for epidermal stratification. This novel finding has
considerable implications regarding tissue engineering.
Keywords Amniocytes  Amniotic fluid  Mesenchymal
stem cells  Skin  Tissue engineering  Collagen hydrogel
Introduction
The composition of the amniotic fluid changes with gesta-
tional age. Whereas in the first half of gestation most of the
fluid comes from active sodium and chloride transport across
the amniotic membrane and the fetal skin, most of the fluid in
the second half of gestation results from fetal micturition and
lung water production [1]. The cells found in this fluid stem
from all three germ layers and stem from the fetal skin, the
digestive tract, and from the amniotic membranes [2].
Among the heterogeneous population of fetal cells that can
be found in the amniotic fluid are mesenchymal, hemato-
poietic, epithelial, and trophoblastic cells [3].
Previous studies showed that the mesenchymal cells
from the amniotic fluid (in this study, referred to as
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amniocytes) express a phenotypic profile that is consistent
with the profile of fetal mesenchymal progenitor cells, i.e.,
they are negative for CD31 and positive for vimentin, a-
smooth muscle actin, keratin 8 and 18, and fibroblast sur-
face protein [4, 5]. They express several, but not all,
important markers for embryonic stem cells, i.e., they are
positive for Oct-4, Nanog, and SSEA-4, indicating that
they represent a new class of stem cells, situated between
embryonic stem cells and adult stem cells [3, 6]. It was
shown that amniocytes have an expansion capacity four to
eightfold higher than bone marrow derived mesenchymal
stem cells, and that they differentiate into various mesen-
chymal lineages, including fibroblasts, osteocytes, and
adipocytes [7]. In culture, these cells secrete various
cytokines and chemokines important for wound healing,
such as IL-6, IL-8, TGF-b, TNFRI, VEGF, and EGF [8].
Culturing of these cells was successful over a period of
8 months with stable karyotype [9]. In addition, it was
shown that amniocytes retain their proliferative capacity
and differentiation potential also during decades of cryo-
preservation [10].
Autologous fetal tissue engineering was performed in
different animal models for various postnatal surgical
interventions such as bladder augmentation, diaphragmatic
replacement, tracheal augmentation, and skin defects [11–
14]. Of note, in these models, tissue engineering was per-
formed using a biopsy from the respective organ and the
engineered tissue was delivered only after birth.
For fetal tissue engineering purposes, the amniotic fluid is
a very attractive cell source. Cells can easily be harvested
from amniotic fluid aspirated during the frequently per-
formed diagnostic amniocenteses [5]. The goal of this paper
was to test whether amniocytes could be used for tissue
engineering of skin. In particular, we wanted to investigate
whether these amniocytes finally can assume anatomically
and functionally the role of dermal fibroblasts.
Materials and methods
Cell harvest and culture
Human skin samples were obtained after informed consent
from patients and/or parents; all described studies were
approved by the Medical Ethical Committee of the Kanton
Zurich. Human primary fibroblasts and keratinocytes were
isolated and cultured according to the standard protocol as
previously described [15].
Confluent back-up human amniocentesis cultures were
received after informed consent of the patients from the
clinical cytogenetics laboratory of the University Medical
Center Groningen. Cells were cultured from healthy fetuses
(with a normal karyotype). Cells were harvested and
expanded in DMEM (Lonza, Breda, The Netherlands)
supplemented with 20 % fetal calf serum (FCS; Perbio
Science, Ettenleur, The Netherlands) and 1 % penicillin,
1 % streptomycin (10,000 U/ml, Gibco, Paisley, UK), and
2 mM L-glutamine (Lonza, Breda, The Netherlands).
Engineering of dermo-epidermal skin substitutes
Skin grafts with either normal human dermal fibroblasts or
human amniocytes in the dermis were prepared, using a
previously established transwell system [6-well cell culture
inserts with membranes of 3 lm pore-size (BD Falcon,
Basel, Switzerland)] [15–17]. As negative control, skin
substitutes with an acellular dermis were produced.
Briefly, bovine collagen type I (BD Biosciences, Basel,
Switzerland) was mixed with either 1 9 105 human pri-
mary dermal fibroblasts or with 1 9 105 human amnio-
cytes, or, for the negative control, no cells, and neutralized
with a buffer containing NaOH [18]. The solution was
poured into the cell culture inserts. The hydrogels were
plastically compressed [19] and cultivated in DMEM with
10 % FCS. After 5 days, 7.5 9 105 keratinocytes were
seeded onto the complete surface of all of the hydrogels.
The grafts were cultivated for 3 days under submersed
conditions in Rheinwald and Green keratinocyte medium,
followed by 3 days cultivation at the air–liquid interface
before transplantation onto immuno-incompetent rats.
Medium was changed every 2–3 days.
Bright light microscopy
To compare the morphology of amniocytes and fibroblasts,
bright light microscopic pictures were taken using a Nikon
SMZ1500 stereo microscope with a Nikon DXM1200F
camera.
Fluorescein diacetate live cell staining
The viability and morphological shape of the cells incor-
porated into the collagen type I hydrogels was compared
using fluorescein diacetate (FdA) live cell staining [20].
Cell culture medium was removed and the hydrogels were
incubated with 5 lM FdA (Sigma, Buchs, Switzerland) in
PBS (Invitrogen, Basel, Switzerland). After 2 min, the FdA
solution was removed and the hydrogels were washed with
PBS. Fluorescein fluorescence was observed using a Nikon
SMZ1500 fluorescent stereo microscope (FITC filter, Ni-
kon DXM1200F camera).
Transplantation of dermo-epidermal skin grafts
Animal experiments were approved by the local committee
for Experimental Animal Research. Immuno-incompetent
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nu/nu rats (age 8–10 weeks, Harlan, Horst, The Nether-
lands) were prepared as previously described [16, 17, 21,
22]. To prevent wound closure by the surrounding skin,
steel rings (diameter 26 mm) were implanted into full-
thickness skin defects on the back of the rats and served as
a modified Fusenig chamber [23]. The transplants were
inserted into the ring and covered with a silicon foil (Silon-
SES, BMS, Allentown, PA, USA). Animal numbers were:
amniocyte-grafts excised 7 days post transplantation
(n = 6); amniocyte-grafts excised 21 days post transplan-
tation (n = 6); fibroblast-grafts excised 7 days post trans-
plantation (n = 6); fibroblast-grafts excised 21 days post
transplantation (n = 6); grafts with acellular dermal part
excised 21 days post transplantation (n = 6). Wound
dressing changes and photographic documentations (Nikon
D90) were performed every 7 days. Animals were killed 7
or 21 days post transplantation. Transplants were excised,
halved, and embedded in O.C.T compound (Tissue-Tek,
Sakura Finetek, Japan), or fixed in 4 % paraformaldehyde
(Medite Medizintechnik AG, Nunningen, Switzerland) and
embedded in paraffin (McCormick, Richmond, USA).
Histology and immunofluorescence
Paraffin sections (sectioned at 10 lm with a microtome
from Leica, Wetzlar, Germany) were deparaffinized and
stained with hematoxylin & eosin (Sigma, Buchs, Swit-
zerland) and imaged by light microscopy (Nikon Eclipse
TE2000-U inverted microscope connected with a
DXM1200F digital camera (Nikon AG, Egg, Switzerland).
O.C.T-embedded tissue was frozen at -20 C and sec-
tioned at 10 lm (Leica, Wetzlar, Germany). Sections were
permeabilized in ice-cold acetone for 5 min, air-dried, and
washed three times with phosphate buffered saline (PBS,
Invitrogen, Basel, Switzerland). Blocking was performed
with PBS containing 2 % bovine serum albumin (Sigma,
Buchs, Switzerland) for 30 min at room temperature.
Sections were incubated with the pre-labeled antibodies for
1 h at room temperature. After three washing steps with
PBS, nuclei were stained with 1 lg/ml Hoechst 33341
(Sigma, Buchs, Switzerland) in PBS for 5 min at room
temperature. After two final washing steps with PBS,
sections were mounted with Dako fluorescent mounting
solution (Dako, Baar, Switzerland).
Antibodies
The following antibodies were used: K1 (clone LHK1,
1:200, Novus Biologicals, Littleton, USA); K15 (clone
SMP190, 1:50, Spring Biosciences, Fermont, USA); K16
(clone LL025, 1:100, Chemicon International, Temecula,
USA); K19 (clone RCK108, 1:100, Dako, Glostrup, Den-
mark); Ki67 (clone B56, 1:100, ABD Serotec, Dusseldorf,
Germany); Lam5a3 (clone P3H9-2, 1:100, Santa Cruz,
Labforce AG, Nunningen, Switzerland) [24].
For immunofluorescence stainings, primary antibodies
were pre-labeled with either Alexa488 or Alexa555 con-
jugated polyclonal goat F(ab’)2 fragments, according to the
manufacturer’s instructions (Zenon Mouse IgG Labelling
Kit, Molecular Probes, Invitrogen, Basel, Switzerland).
Fluorescence microscopy
Immunofluorescence stainings were analyzed using a Ni-
kon Eclipse TE2000-U inverted microscope, equipped with
Hoechst, FITC and TRICT filter sets and connected with a
DXM1200F digital camera (Nikon AG, Egg, Switzerland).
Images were processed with Photoshop 7.0 (Adobe Sys-
tems Inc., Munich, Germany).
Results
Amniotic fluid derived cells
Mesenchymal cells from human amniotic fluid (amnio-
cytes) were isolated, cultured and passaged several times.
Upon 90–100 % confluence, the amniocytes (Fig. 1a)
demonstrated a rather irregular arrangement as opposed to
the one of human fibroblasts (Fig. 1b) that appeared to be
more ‘‘streamlined’’. The amniocytes shared the spindle-
shaped morphology with fibroblasts.
Amniocytes were incorporated into bovine collagen type
I hydrogels and FdA staining was performed 3 days
thereafter to assess the viability of the cells as well as their
morphology in this 3D culture system. FdA staining
revealed high cell viability with spindle-shaped, dendrite,
or stellate morphology of the cells (Fig. 1c), similar to
fibroblasts in collagen hydrogel (Fig. 1d).
Macroscopic appearance of epidermis development
on transplanted grafts
At transplantation of the three types of skin substitutes
(amniocytes in the dermis, fibroblasts in the dermis, or,
acellular dermis) on the back of immuno-incompetent rats,
no macroscopic difference between the three types of
transplants could be observed (Fig. 2a–c). Seven days post
transplantation, complete take of all grafts in all animals was
observed (Fig. 2d–f). The presence or absence of an epi-
dermis was difficult to asses macroscopically at this early
stage, although the transplants with acellular dermis
appeared to have a rather moist surface (Fig. 2f), usually
indicating a missing or poorly developed epidermis. Twenty-
one days post transplantation, grafts containing amniocytes
or fibroblasts showed a clearly epithelialized surface and
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seemed well integrated into the rat tissue (Fig. 2g, h). Grafts
with an acellular dermis had a moist surface (Fig. 2i) and
appeared smaller compared to the other transplants.
Histological analysis of the epidermis
Excised grafts were sectioned and stained with hematox-
ylin & eosin. Seven days post transplantation, skin sub-
stitutes with amniocytes (Fig. 3a) showed a stratified
epidermis of 4–6 keratinocyte layers with near-normal
anatomy and a stratum corneum. The dermal part of these
grafts was clearly distinguishable from the underlying tis-
sue, and evenly distributed cells could be detected in the
dermis (Fig. 3a). Similar features were observed in grafts
with fibroblasts (Fig. 3b). Twenty-one days post trans-
plantation, the neodermis in transplants with amniocytes
and with fibroblasts showed a higher cell number than
7 days post transplantation, and the epidermis demon-
strated about 6–8 layers on the amniocyte-grafts (Fig. 3c)
and about 8–10 layers on the fibroblast-grafts (Fig. 3d).
Twenty-one days post transplantation, a large part of the
dermis in grafts with acellular dermis was devoid of any
cells, and no epidermal elements were detectable (Fig. 3e).
Basal lamina deposition, epidermal homeostasis
and proliferation
Grafts excised 21 days post transplantation were sectioned
and immunofluorescence stainings were performed. Staining
of the amniocyte-grafts with an antibody to the basal lamina
component laminin 5 (Fig. 4a) demonstrated a deposition of
a continuous basal lamina in all transplants and keratin 1
expression was not fully established in all suprabasal layers
(Fig. 4a). In fibroblast-grafts in the dermis, laminin 5 stain-
ing revealed a continuous basal lamina and keratin 1 was
expressed in all suprabasal layers (Fig. 4b). In amniocyte-
grafts, keratin 16 was continuously expressed in all supra-
basal layers (Fig. 4c). Amniocyte-grafts demonstrated more
cells expressing the proliferation marker Ki67 in the basal
layer (Fig. 4c), while the fibroblast-grafts demonstrated
more Ki67 positive cells in the dermis (Fig. 4d). In fibro-
blast-grafts, keratin 16 expression was found in all supra-
basal layers (Fig. 4d). In amniocytes-grafts, keratin 15
expression could be observed in most of the basal cells,
whereas expression of keratin 19 was detected in most su-
prabasal cells (Fig. 4e). In fibroblast-grafts, keratin 15
expression was found in most basal cells, and a subpopula-
tion of these basal cells was positive for keratin 19 (Fig. 4f).
Discussion
We describe here the generation of dermo-epidermal skin
grafts containing human primary amniotic fluid derived
cells in the dermis instead of human fibroblasts. These
tissue-engineered skin substitutes were compared to tissue-
engineered dermo-epidermal skin substitutes with human
primary fibroblasts in the dermis and grafts with an
Fig. 1 Comparison of
morphology of human primary
amniocytes and human primary
fibroblasts on cell culture plastic
(2D) and in a collagen hydrogel
(3D). a Phase contrast
microscopy of amniocytes
shows cell morphology similar
to spindle-shape morphology of
fibroblasts (b). c Positive
fluorescein diacetate staining of
amniocytes in collagen hydrogel
shows dendrite morphology and
good viability of the cells.
d Fluorescein diacetate staining
of fibroblasts indicating high
viability as seen by the mainly
dendrite or stellate morphology.
Scale bars 40 lm
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acellular dermis. The key finding of our study is that the
amniocytes can competently substitute for fibroblasts and
successfully support epidermis stratification and survival.
Some aspects deserve detailed consideration.
The interaction between epithelium and underlying
mesenchyme was studied extensively for many years. It
became clear that for successful epidermal stratification
and survival, an underlying mesenchyme is absolutely
mandatory. The mesenchyme provides essential growth
factors to the epithelial cells and so stimulates the strati-
fication of the epidermis [25–28].
It was therefore not surprising that we could not observe
epidermis stratification, nor survival, in our skin grafts
created with an acellular dermis. Interestingly, transplants
Fig. 2 Macroscopic views of grafts at time point of transplantation
(day 0), 7 and 21 days post transplantation. a–c Transplants show
similar appearance at the day of transplantation. d, e Seven days post
transplantation, the surface of both amniocyte- and fibroblast-grafts is
similar and looks rather dull and dry. f Grafts with acellular dermis
appear more shiny and moist. g, h Twenty-one days post transplan-
tation, grafts with amniocytes and with fibroblasts look similar as
shown in d, e. i Twenty-one days post transplantation, grafts with
acellular dermis look similar as described in f. Diameter of the ring
(arrow in a) 26 mm (a–i)
Pediatr Surg Int (2013) 29:61–69 65
123
with amniocytes in the dermis showed near-normal struc-
ture, comparable to control transplants with fibroblasts in
the dermis. The epithelial cells in amniocyte-grafts strati-
fied to a near-normal epidermis including a stratum cor-
neum and deposited a continuous basal lamina. However,
expression patterns for markers of epidermal homeostasis
suggested that 21 days post transplantation the epidermis
was not yet in a fully homeostatic state. This aspect was
reinforced by the detection of many suprabasal cells that
were positive for keratin 19 expression, compared to the
fibroblast-grafts where keratin 19 expression was restricted
to some basal cells. These findings indicate that the
development of the epidermis within amniocyte containing
grafts is basically physiological, but slightly slower than in
those containing fibroblast. These results provide
compelling evidence that amniocytes incorporated into the
dermal part of a dermo-epidermal skin graft can efficiently
substitute fibroblasts and correctly support epidermal sur-
vival and stratification.
Diagnostic amniocentesis is routinely offered, can be
safely performed under ultrasound guidance, and is asso-
ciated with a very low rate of spontaneous abortion of only
0.5 % [29]. The removal of an additional small aliquot of
amniotic fluid does not represent an additional risk to fetus
or mother and also does not apparently constitute an ethical
concern.
The present study can be seen as a first step toward
tissue engineering of fetal skin without the necessity of
harvesting a formal fetal skin biopsy. We demonstrate that
prenatally harvested amniocytes can be successfully
Fig. 3 Histological evaluation
of the excised grafts
(hematoxylin & eosin staining).
a Seven days post
transplantation, amniocyte-
grafts show a correctly stratified
epidermis with 4–6 cell layers
and a stratum corneum. The
collagen gel is easily
discernable. b Seven days post
transplantation, fibroblast-grafts
look similar as described in
a. The collagen gel is similar as
in a. c Twenty-one days post
transplantation, the epidermis of
amniocyte-grafts is near
physiological and has 6–8 cell
layers. The dermis is markedly
populated by cells. d Twenty-
one days post transplantation,
the epidermis of fibroblast-
grafts is up to 8–10 cell layers
thick including stratum
corneum, and the dermis is
densely populated by cells.
e Twenty-one days post
transplantation, grafts with
acellular dermis show neither
epidermis nor single epidermal
cells. The collagen gel is easily
detectable and a large part of it
does not contain cells. The
dotted line indicates the border
between graft and underlying
tissue. Arrows point at stratum
corneum. cg Collagen gel. Scale
bars 100 lm (a–e)
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employed to competently assume the role of dermal
fibroblasts in a fetal-postnatal hybrid skin substitute (am-
niocytes = fetal cells, keratinocytes = postnatal cells). Of
note, amniotic fluid also contains fetal epidermal cells that,
hypothetically, might also be harvested, isolated, cultured,
so as to form a fetal epidermis. Taken together, in a best
case future scenario, autologous ‘‘fetal skingineering’’
could be accomplished by the sole use of amniotic fluid.
What are then, theoretically, possible applications for
such laboratory-grown fetal skin? Human fetal surgery
for spina bifida is a reality today and represents a novel
standard of care for select fetuses suffering from that
devastating malformation [30] (also at our center [31]).
Quite often, the back lesions of these fetal patients are
very big for successful primary skin closure. In those
situations, an ‘‘off-the-shelf’’ autologous fetal skin sub-
stitute might represent an ideal way to guarantee ade-
quate skin coverage. Another hypothetical application
might be the use of amniotic fluid derived bioengineered
fetal skin to treat chronic skin wounds, particularly in
polymorbid elderly patients which often demonstrate
notorious wound healing problems. It is in fact con-
ceivable that fetal skin (even if allogenic) harbors more
wound healing power [8] than postnatal skin substitutes
used for the same purpose [32, 33]. Finally, one could
even think of harvesting and cryopreserving amniotic
fluid for any potential use later in life. It was in fact
shown that stored amniocytes remain viable and func-
tional over decades of cryopreservation [10]. If the same
holds true for amniotic fluid derived epidermal cells,
Fig. 4 Immunofluorescence
stainings of grafts with
amniocytes or with fibroblasts
in the dermis 21 days after
transplantation. a, b Staining of
the basement membrane
component laminin 5 (red)
reveals the deposition of a
continuous basement membrane
in both types of transplants.
Expression of keratin 1 (green)
is not fully established in all
suprabasal layers in amniocyte-
grafts, whereas in fibroblast-
grafts, all suprabasal layers
express keratin 1. c, d In both
types of transplants, keratin 16
(red) is expressed in all
suprabasal layers. Proliferation
as indicated by expression of
Ki67 (green) in the basal cell
layer of amniocyte-grafts is
more pronounced compared to
fibroblast-grafts. Proliferation of
cells in the dermal part is lower
in amniocyte-grafts than in
fibroblast-grafts. e, f In
amniocyte-grafts, keratin 19
(red) expression is detected in
most suprabasal cells, whereas
in fibroblast-grafts keratin 19
expression is restricted to some
basal cells. In both types of
grafts, keratin 15 expression
(green) is detected in some
basal cells. Scale bars 50 lm
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then autologous skin might be engineered at any age of
the patient for a number of possible indications (giant
nevi, burns, scar revisions, chronic wounds, and other
conditions where larger areas of skin are lost).
In summary and conclusion, we demonstrate here that
amniocytes can competently assume the role of dermal
fibroblasts in the context of bioengineering a full-thickness
skin analog. This novel finding has fundamental implica-
tions on the emerging field of tissue engineering and har-
bors considerable potential regarding in vitro fabrication of
both fetal and adult skin.
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